Phase 1 Stomach Cancer Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- Adults aged 18 or older, of any gender
- People who have been confirmed by tissue testing to have an advanced, spreading, or returning cancer — mainly colorectal, esophageal, stomach, pancreatic, lung, or bile duct cancer
- People whose cancer has not responded to at least two prior standard treatments (such as surgery, chemotherapy, or radiotherapy), or who cannot tolerate further standard treatment, or for whom no effective treatment options remain
- People whose tumor sample tests positive for a protein called CEA (at least 10% of cells showing clear staining on the cell surface) within the past 3 months — or, if the test is older than 3 months, a blood CEA level above 10 µg/L is also required
- People who have at least one measurable or assessable area of cancer that can be tracked during the trial
- People who have a general health performance score of 0, 1, or 2 on the ECOG scale, meaning they are able to carry out some or all daily activities (confirm with trial site)
- People whose doctors estimate they are likely to live at least 12 weeks
- People without severe psychiatric disorders
- People whose blood counts, heart function, kidney function, liver function, and oxygen levels meet the specific thresholds set by the trial (confirm with trial site for exact values)
- People who are able to give blood or have cells collected without any medical reason preventing this
- People who agree to use reliable contraception (not the rhythm method) from the time of signing consent until one year after receiving the treatment
- People (or their legal guardian) who agree to take part and sign the informed consent form after being informed of the trial's purpose and procedures
Who may not be able to join:
- People who have cancer that has spread to the brain or the lining around the brain and is causing active symptoms, or where this spread is considered uncontrolled by the treating doctor
- People who have taken part in another clinical trial within the past month before screening
- People who received a live vaccine within 4 weeks before screening
- People who received chemotherapy, targeted therapy, or other experimental cancer treatments within 14 days (or within 5 half-lives of the drug, whichever is shorter) before screening
- People who have an active infection that requires treatment throughout the body, or an infection that is not under control
- People who have a bowel blockage, active bleeding in the digestive tract, a history of serious gastrointestinal bleeding in the past 3 months, or severe conditions such as serious stomach or intestinal ulcers, severe ulcerative colitis, or other serious digestive tract inflammation
- People who still have side effects from previous cancer treatments that have not returned to their pre-treatment level or are worse than mild (grade 1), except for hair loss or nerve-related tingling or numbness
- People with certain heart conditions, including: severe heart failure (NYHA Class III or IV); a heart attack or heart bypass surgery within the past 6 months; significant irregular heart rhythms or unexplained fainting episodes (unless caused by a known non-heart-related reason); or severe non-ischemic heart muscle disease
- People with active autoimmune diseases or conditions that require long-term use of medicines that suppress the immune system
- People who have had another type of cancer in the past 3 years, unless it was cervical cancer in situ or basal cell skin cancer that has been treated and is stable
- People who test positive for hepatitis B, hepatitis C, HIV, or syphilis under the specific conditions described in the trial criteria (confirm with trial site for details)
- People who are pregnant or breastfeeding
- People whom the trial doctor considers unsuitable for any other reason
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Donglai Lv, MD, The 901 Hospital of Joint Logistics Support Force of People Liberation Army
Phone: +86 13655600090
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
To evaluate the safety of CAR-T cell preparations in the treatment of CEA-positive advanced malignancies [Safety and Tolerability]; Obtained the recommended dose and infusion regimen of CAR-T cells for the treatment of patients with CEA-positive advanced malignancies[Safety and Tolerability]
Can't join this trial?
Data last synced from ClinicalTrials.gov: 22 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.